| MYD88 L265P somatic mutation in Waldenström's macroglobulinemia SP Treon, L Xu, G Yang, Y Zhou, X Liu, Y Cao, P Sheehy, RJ Manning, ... New England Journal of Medicine 367 (9), 826-833, 2012 | 1532 | 2012 |
| Ibrutinib in previously treated Waldenström’s macroglobulinemia SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ... New England Journal of Medicine 372 (15), 1430-1440, 2015 | 1037 | 2015 |
| The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B … ZR Hunter, L Xu, G Yang, Y Zhou, X Liu, Y Cao, RJ Manning, C Tripsas, ... Blood, The Journal of the American Society of Hematology 123 (11), 1637-1646, 2014 | 536 | 2014 |
| MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele … L Xu, ZR Hunter, G Yang, Y Zhou, Y Cao, X Liu, E Morra, A Trojani, ... Blood, The Journal of the American Society of Hematology 121 (11), 2051-2058, 2013 | 459 | 2013 |
| Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia SP Treon, Y Cao, L Xu, G Yang, X Liu, ZR Hunter Blood, The Journal of the American Society of Hematology 123 (18), 2791-2796, 2014 | 439 | 2014 |
| A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia G Yang, Y Zhou, X Liu, L Xu, Y Cao, RJ Manning, CJ Patterson, ... Blood, The Journal of the American Society of Hematology 122 (7), 1222-1232, 2013 | 423 | 2013 |
| Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism E Hatjiharissi, L Xu, DD Santos, ZR Hunter, BT Ciccarelli, S Verselis, ... Blood, the Journal of the American Society of Hematology 110 (7), 2561-2564, 2007 | 329 | 2007 |
| MYD88 mutations and response to ibrutinib in Waldenström's macroglobulinemia SP Treon, L Xu, Z Hunter New England Journal of Medicine 373 (6), 584-586, 2015 | 276 | 2015 |
| The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia Y Cao, ZR Hunter, X Liu, L Xu, G Yang, J Chen, CJ Patterson, ... Leukemia 29 (1), 169-176, 2015 | 254 | 2015 |
| Characterization of familial Waldenström's macroglobulinemia SP Treon, ZR Hunter, A Aggarwal, EP Ewen, S Masota, C Lee, DD Santos, ... Annals of Oncology 17 (3), 488-494, 2006 | 231 | 2006 |
| Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248 SP Treon, ZR Hunter, J Matous, RM Joyce, B Mannion, R Advani, D Cook, ... Clinical cancer research 13 (11), 3320-3325, 2007 | 223 | 2007 |
| Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia SP Treon, J Gustine, K Meid, G Yang, L Xu, X Liu, M Demos, A Kofides, ... Journal of Clinical Oncology 36 (27), 2755-2761, 2018 | 195 | 2018 |
| Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs X Leleu, J Soumerai, A Roccaro, E Hatjiharissi, ZR Hunter, R Manning, ... Journal of Clinical Oncology 27 (2), 250-255, 2009 | 195 | 2009 |
| Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia SP Treon, CK Tripsas, K Meid, S Kanan, P Sheehy, S Chuma, L Xu, ... Blood, The Journal of the American Society of Hematology 124 (4), 503-510, 2014 | 193 | 2014 |
| Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia SP Treon, AR Branagan, Z Hunter, D Santos, O Tournhilac, KC Anderson Annals of oncology 15 (10), 1481-1483, 2004 | 178 | 2004 |
| Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies SP Treon, L Xu, ML Guerrera, C Jimenez, ZR Hunter, X Liu, M Demos, ... Journal of Clinical Oncology 38 (11), 1198-1208, 2020 | 166 | 2020 |
| Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia SP Treon, K Meid, J Gustine, G Yang, L Xu, X Liu, CJ Patterson, ... Journal of Clinical Oncology 39 (6), 565-575, 2021 | 158 | 2021 |
| Thalidomide and rituximab in Waldenstrom macroglobulinemia SP Treon, JD Soumerai, AR Branagan, ZR Hunter, CJ Patterson, ... Blood, The Journal of the American Society of Hematology 112 (12), 4452-4457, 2008 | 157 | 2008 |
| Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia L Xu, ZR Hunter, N Tsakmaklis, Y Cao, G Yang, J Chen, X Liu, S Kanan, ... British journal of haematology 172 (5), 735-744, 2016 | 156 | 2016 |
| Overall survival and competing risks of death in patients with W aldenström macroglobulinaemia: an analysis of the S urveillance, E pidemiology and E nd R esults database JJ Castillo, AJ Olszewski, S Kanan, K Meid, ZR Hunter, SP Treon British Journal of Haematology 169 (1), 81-89, 2015 | 152 | 2015 |
